⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TLX News
Telix Pharmaceuticals Limited American Depositary Shares
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
globenewswire.com
TLX
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
globenewswire.com
TLX
FDA Alignment to Advance ProstACT Global Phase 3 Trial
globenewswire.com
TLX
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
globenewswire.com
TLX
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN
Telix and United Imaging Announce Strategic Theranostics Collaboration
globenewswire.com
TLX
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
globenewswire.com
TLX
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
globenewswire.com
TLX
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
globenewswire.com
TLX
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
globenewswire.com
TLX
EDAP
PROF